Ozanimod 28-Day Starter Kit
RxNorm 2642213
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2642213 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ozanimod 28-Day Starter Kit.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
PSNPrescribable
Prescribable Name (PSN):
Ozanimod 28-Day Starter Kit
(Atom ID: 12822178)
SYPrescribable
Synonym (SY):
Ozanimod 28-Day Starter Kit (7-Day Starter Pack and 0.92 mg 21 count Bottle)
(Atom ID: 12822177)
GPCKPrescribable
Generic Pack (GPCK):
{4 (ozanimod 0.23 mg Oral Capsule) / 3 (ozanimod 0.46 mg Oral Capsule) / 21 (ozanimod 0.92 mg Oral Capsule) } Pack
(Atom ID: 12822167)
Patient Education
Ozanimod
Ozanimod is used to treat adults with relapsing forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). It is also used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults. Ozanimod is in a class of medications called sphingosine l-phosphate receptor modulators. It works by decreasing the action of immune cells that may cause nerve damage.
[Learn More]
* Please review the disclaimer below.